Brokerages Set Krystal Biotech, Inc. (NASDAQ:KRYS) Target Price at $197.00

Krystal Biotech, Inc. (NASDAQ:KRYS) has been assigned a consensus rating of “Buy” from the nine research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $197.00.

KRYS has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Tuesday, November 5th. William Blair raised Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Citigroup lifted their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Stifel Nicolaus raised their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Finally, Evercore ISI upped their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a report on Monday, August 12th.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This represents a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 14.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

Institutional investors have recently modified their holdings of the business. Swiss National Bank boosted its stake in Krystal Biotech by 0.8% during the 1st quarter. Swiss National Bank now owns 36,200 shares of the company’s stock valued at $6,441,000 after purchasing an additional 300 shares during the period. Sei Investments Co. lifted its holdings in Krystal Biotech by 128.3% in the 1st quarter. Sei Investments Co. now owns 33,752 shares of the company’s stock valued at $6,005,000 after acquiring an additional 18,968 shares during the last quarter. Headlands Technologies LLC bought a new stake in Krystal Biotech during the first quarter worth approximately $291,000. ProShare Advisors LLC boosted its stake in shares of Krystal Biotech by 9.0% during the 1st quarter. ProShare Advisors LLC now owns 5,865 shares of the company’s stock worth $1,044,000 after acquiring an additional 486 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System boosted its position in shares of Krystal Biotech by 18.5% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 7,307 shares of the company’s stock valued at $1,300,000 after purchasing an additional 1,140 shares during the period. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

KRYS stock opened at $177.39 on Tuesday. The stock has a 50-day simple moving average of $181.27 and a 200-day simple moving average of $181.38. The firm has a market cap of $5.10 billion, a P/E ratio of 104.08 and a beta of 0.82. Krystal Biotech has a 1 year low of $96.73 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same quarter last year, the company earned ($0.67) earnings per share. Krystal Biotech’s revenue for the quarter was up 879.9% on a year-over-year basis. On average, equities research analysts predict that Krystal Biotech will post 2.97 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).